产品
编 号：F112745
分子式：C26H40N4O9S
分子量：584.68
分子式：C26H40N4O9S
分子量：584.68
产品类型
规格
价格
是否有货
1mg
询价
询价
5mg
询价
询价
结构图
CAS No: 129981-36-8
产品详情
生物活性：
Sampatrilat (UK-81252) is a potent and orally active vasopeptidase inhibitor of ACE and neutral endopeptidase (NEP). Sampatrilat inhibits C-domain ACE (Ki=13.8 nM) 12.4-fold more potent than that for the N-domain (Ki=171.9 nM). Sampatrilat (UK-81252) can be used for the study of chronic heart failure and blood pressure regulation.
体内研究：
Sampatrilat (oral adminstration; 30 mg/kg; once a day; 5 weeks)reduces the mortality of the rats with CAL (20% versus 57% for untreatedrats) and increase in the survival rate and improvement of hemodynamic function of the rats with CAL. This compound suppresses tissue ACE and neutral endopeptidase (NEP) activities, but it does not affect the arterial blood pressure, whereas it attenuates the CAL-induced increases in the left ventricular end-diastolic pressure, heart weight, and collagen content of the viable left Ventricle.Animal Model:Left coronary artery ligation (CAL) and sham-operated rats
Dosage:30 mg/kg
Administration:Oral adminstration
Result:Prevented the increases in heart weight and cardiac collagen content of the rats with CAL.
Sampatrilat (UK-81252) is a potent and orally active vasopeptidase inhibitor of ACE and neutral endopeptidase (NEP). Sampatrilat inhibits C-domain ACE (Ki=13.8 nM) 12.4-fold more potent than that for the N-domain (Ki=171.9 nM). Sampatrilat (UK-81252) can be used for the study of chronic heart failure and blood pressure regulation.
体内研究：
Sampatrilat (oral adminstration; 30 mg/kg; once a day; 5 weeks)reduces the mortality of the rats with CAL (20% versus 57% for untreatedrats) and increase in the survival rate and improvement of hemodynamic function of the rats with CAL. This compound suppresses tissue ACE and neutral endopeptidase (NEP) activities, but it does not affect the arterial blood pressure, whereas it attenuates the CAL-induced increases in the left ventricular end-diastolic pressure, heart weight, and collagen content of the viable left Ventricle.Animal Model:Left coronary artery ligation (CAL) and sham-operated rats
Dosage:30 mg/kg
Administration:Oral adminstration
Result:Prevented the increases in heart weight and cardiac collagen content of the rats with CAL.
产品资料
Copyright©2015-2024 沪ICP备2022026524号-1
沪公网安备